120-26-3

Basic information

• Product Name: 3,4-dimethoxy-alpha-methylphenethylamine
• Synonyms: 3,4-dimethoxy-alpha-methylphenethylamine;3,4-dimethoxyamphetamine;3-(3,4-Dimethoxyphenyl)-2-propanamine;3,4-Dimethoxy-α-methylbenzeneethanamine;α-Methyl-3,4-dimethoxybenzeneethanamine;α-Methyl-3,4-dimethoxyphenethylamine;13078-75-6 (Hydrochloride);3,4-Dimethoxyphenylisopropylamine
• CAS NO: 120-26-3
• Molecular Formula: C₁₁H₁₇NO₂
• Molecular Weight: 195.25818
• EINECS: 204-383-7
• Mol File: 120-26-3.mol

Chemical Properties

• Melting Point: 39-40 °C
• Boiling Point: 289°Cat760mmHg
• Flash Point: 139.8°C
• Appearance: /
• Density: 1.023g/cm³
• PKA: 9.78±0.10(Predicted)
• CAS DataBase Reference: 3,4-dimethoxy-alpha-methylphenethylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-dimethoxy-alpha-methylphenethylamine(120-26-3)
• EPA Substance Registry System: 3,4-dimethoxy-alpha-methylphenethylamine(120-26-3)

Safety Data

• Hazardous Substances Data: 120-26-3(Hazardous Substances Data)

Upstream product

• 122-47-4 1-(3,4-dimethoxyphenyl)-2-nitropropene 
• 93-15-2 1,2-dimethoxy-4-(2-propenyl)benzene 
• 106273-88-5 3-(3,4-dimethoxy-phenyl)-2-methyl-propionic acid amide 
• 776-99-8 3,4-dimethoxyphenylacetone 
• 77287-34-4 formamide 
• 623-26-7 terephthalonitrile 
• 6379-72-2 1,2-dimethoxy-4-(E)-propenylbenzene 
• 122-47-4 3,4-dimethoxy-β-methyl-β-nitrostyrene 
• 87095-02-1 2-nitro-1-(3,4-dimethoxyphenyl)propane 
• 91994-62-6 N-[2-(3,4-Dimethoxy-phenyl)-1-methyl-ethyl]-2,2,2-trifluoro-acetamide 
• 37629-53-1 (E)-1,2-dimethoxy-4-(2-nitroprop-1-enyl)benzene 
• 7732-18-5 water 
• 10035-10-6 hydrogen bromide 
• 1454-62-2 (3,4-dimethoxy-phenyl)-acetone oxime 

Downstream Products

• 3979-57-5 (3,4-dimethoxy-phenyl)-acetic acid-[2-(3,4-dimethoxy-phenyl)-1-methyl-ethylamide] 
• 5884-29-7 6,7-dimethoxy-3-methyl-3,4-dihydro-isoquinoline; hydrochloride 
• 103330-49-0 N,N'-bis-[2-(3,4-dimethoxy-phenyl)-1-methyl-ethyl]-adipamide 
• 33236-61-2 1-(3,4-dimethoxyphenyl)-N-methylpropan-2-amine 
• 555-64-6 α-methyldopamine 
• 103266-52-0 1-(3,4-bis-benzyloxy-phenyl)-2-[2-(3,4-dimethoxy-phenyl)-1-methyl-ethylamino]-ethanone 
• 124676-13-7 [2-(3,4-Dimethoxy-phenyl)-1-methyl-ethyl]-[2-(3,4-dimethoxy-phenyl)-1-methyl-eth-(E)-ylidene]-amine 
• 78351-31-2 1-[2-(3,4-Dimethoxy-phenyl)-1-methyl-ethylamino]-3-{2-[(E)-2-(3-methyl-isoxazol-5-yl)-vinyl]-phenoxy}-propan-2-ol 
• 65008-89-1 5-{3-[2-(3,4-Dimethoxy-phenyl)-1-methyl-ethylamino]-2-hydroxy-propoxy}-8-(2-methoxy-ethoxy)-3,4-dihydro-1H-quinolin-2-one 
• 80090-11-5 8-Benzyloxy-5-{3-[2-(3,4-dimethoxy-phenyl)-1-methyl-ethylamino]-2-hydroxy-propoxy}-3,4-dihydro-1H-quinolin-2-one 
• 91944-43-3 1-[2-(3,4-Dimethoxy-phenyl)-1-methyl-ethylamino]-3-[4-(5-thiophen-2-yl-1H-imidazol-2-yl)-phenoxy]-propan-2-ol 
• 142893-52-5 1-(2-nitro-4,5-dimethoxyphenyl)-2-aminopropane 
• 51920-75-3 N-[2-(3,4-dimethoxy-phenyl)-1-methyl-ethyl]-acetamide 
• 17254-09-0 3.4-Dimethoxy-1-(2-propionylaminopropyl)-benzol 

Relevant articles and documents

Transaminase-mediated synthesis of enantiopure drug-like 1-(3′,4′-disubstituted phenyl)propan-2-amines

Transaminases (TAs) offer an environmentally and economically attractive method for the direct synthesis of pharmaceutically relevant disubstituted 1-phenylpropan-2-amine derivatives starting from prochiral ketones. In this work, we report the application of immobilised whole-cell biocatalysts with (R)-transaminase activity for the synthesis of novel disubstituted 1-phenylpropan-2-amines. After optimisation of the asymmetric synthesis, the (R)-enantiomers could be produced with 88-89% conversion and >99% ee, while the (S)-enantiomers could be selectively obtained as the unreacted fraction of the corresponding racemic amines in kinetic resolution with >48% conversion and >95% ee. This journal is

Stereoselective Synthesis of 1-Arylpropan-2-amines from Allylbenzenes through a Wacker-Tsuji Oxidation-Biotransamination Sequential Process

Herein, a sequential and selective chemoenzymatic approach is described involving the metal-catalysed Wacker-Tsuji oxidation of allylbenzenes followed by the amine transaminase-catalysed biotransamination of the resulting 1-arylpropan-2-ones. Thus, a series of nine optically active 1-arylpropan-2-amines were obtained with good to very high conversions (74–92%) and excellent selectivities (>99% enantiomeric excess) in aqueous medium. The Wacker-Tsuji reaction has been exhaustively optimised searching for compatible conditions with the biotransamination experiments, using palladium(II) complexes as catalysts and iron(III) salts as terminal oxidants in aqueous media. The compatibility of palladium/iron systems for the chemical oxidation with commercially available and made in house amine transaminases was analysed, finding ideal conditions for the development of a general and stereoselective cascade sequence. Depending on the selectivity displayed by selected amine transaminase, it was possible to produce both 1-arylpropan-2-amines enantiomers under mild reaction conditions, compounds that present therapeutic properties or can be employed as synthetic intermediates of chiral drugs from the amphetamine family. (Figure presented.).

Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection

The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5 and R6 are as described herein, compositions including the compounds and methods of using the compounds.

NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION

The invention provides novel compounds having the general formula (I) wherein R1, R2 R3, R4, R5 and R6 are as described herein, compositions including the compounds and methods of using the compounds in the treatment of the hepatitis B virus.

Instantaneous SmI2/H2O/amine mediated reduction of nitroalkanes and α,β-unsaturated nitroalkenes

A rapid method for efficient reduction of nitroalkanes and α,β-unsaturated nitroalkenes using SmI2/H2O/amine has been developed.

NOVEL PYRROLODIHYDROISOQUINOLINES AS PDE10 INHIBITORS

The invention relates to novel pyrrolodihydroisoquinoline derivatives, which are efficacious inhibitors of PDE10.

Catalytic N-sulfonyliminium ion-mediated cyclizations to α-vinyl-substituted isoquinolines and β-carbolines and applications in metathesis

Catalytic Sn(OTf)2-induced cyclization of linear, aryl-containing allylic N,O-acetals produced vinyl-substituted tetrahydroisoquinolines and tetrahydro-1H-β-carbolines. The usefulness of the vinyl moiety in the resulting products was demonstrated via the synthesis of various key building blocks for alkaloid structures. The α-vinyl moiety was utilized in a [2,3] sigmatropic rearrangement, in ring-closing metathesis and a cross-metathesis-based synthesis of vincantril, an antianoxia agent, and a synthetic member of the vincamine type natural products.

1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES, PREPARATIONS THEREOF AND USES THEREOF

Compounds of general formula (I) wherein D, E, R1, R2, R3, R4, R5, R6 and R7 are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs

The present invention comprises novel analogs of ecstasy-class compounds and novel ecstasy-class immunogens leashed out of, i.e., derived from, the methylenedioxy position. The invention also comprises unique monoclonal antibodies generated using MDO-leashed MDMA immunogens as well as unique conjugates and tracers. These antibodies, conjugates, and tracers are useful in immunoassays for the detection of ecstasy-class compounds in biological fluids.

New series of N-substituted phenyl ketone oxime ethers: Synthesis and bovine β3-adrenergic agonistic activities

A series of ten novel phenyl ketone oxime ethers substituted on the terminal nitrogen by either 1,3 benzodioxole, alkyl, aralkyl or aryl moiety were synthesized and tested for their activity at bovine β3-adrenoceptors. The best compound, which was the benzodioxole dicarboxylate derivative, showed potent β3-adrenergic agonistic activities in Chinese hamster ovary cells expressing the bovine β3-adrenoceptors with Kact and Ki values better than compound CL 316,243 used as reference (14 ± 6 nM and 203 ± 71 nM, respectively). In this series three compounds showed an antagonistic activity. Structure-activity relationships in these ketone oxime ethers are discussed.